海利生物（603718）9月15日晚间公告，将瑞盛生物55%股权的收购价格由9.35亿元下调至5.36亿元，业 绩承诺相应调整。海利生物方面表示，在瑞盛生物出现经营业绩下滑的背景下，此举使得公司降低了投 资成本，控制了投资风险，有利于维护公司及全体股东的利益。 公告显示，海利生物收购瑞盛生物55%股权的价格由9.35亿元调整为5.36亿元，同时2025年度和2026年 度的扣非净利润承诺数分别调整为5000万元和5800万元。 这笔收购在去年10月份已经完成，瑞盛生物2024年度的净利润承诺数也已达成。在本次调整后，交易对 手将返还本次调整后的交易价格差额3.99亿元，同时预计也可以调减原收购瑞盛生物时形成的商誉。本 次调整事项尚需提交公司股东会审议。 同时，瑞盛生物原适用的税收优惠政策也出现收紧。瑞盛生物的主营产品以往可申请办理一般纳税人按 3%简易征收增值税，但目前已按税务要求改为一般计税方式即按13%的税率征收增值税。 行业整体处于"价格战"的环境中，作为行业龙头企业，瑞盛生物仍存在一定优势。半年报显示，一方 面，随着新基地的启用，发货量的增加推动瑞盛生物骨粉、骨膜综合市占率相比去年半年度提高了约 6% ...

Policy Developments - Tibet Medical Insurance Bureau issued a statement clarifying that it has not authorized any organization or individual to promote "commercial health insurance" products, urging the public to remain vigilant against fraud [1] - The State Council approved the "Medical and Health Strong Foundation Project Implementation Plan," emphasizing its significance in enhancing grassroots medical service capabilities and promoting health initiatives in China [2] Drug and Device Approvals - Baiyoutai announced that its Adalimumab injection (Qletli®) received marketing approval from the UK MHRA, expanding its overseas sales portfolio and potentially positively impacting long-term performance [3] - Zhixiang Jintai received clinical trial approval for its GR1803 injection for systemic lupus erythematosus, a dual-specific antibody drug targeting BCMA and CD3 [4] - Haili Biological's subsidiary received acceptance for a medical device registration application for a natural bone repair material, classified as a Class III medical device [5] - Xinlitai announced that its Enarodustat tablets received a drug registration certificate for treating anemia in chronic kidney disease patients undergoing dialysis [6] Capital Market Activities - Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. received approval for its listing on the New Third Board, with projected revenues of 446 million yuan and 418 million yuan for 2023 and 2024, respectively [8] - Palin Bio announced a share transfer agreement with China Biologic, involving the transfer of approximately 200 million shares, representing 21.03% of the total share capital, for a total price of about 4.699 billion yuan [9] Industry Events - Aimeike reported that its REGEN company's new factory in South Korea is steadily increasing production since its launch [10] - Novo Nordisk announced a global restructuring plan involving the layoff of approximately 9,000 positions, about 11% of its workforce, aiming for annual cost savings of around 8 billion Danish kroner by 2026 [10] Public Sentiment Alerts - Amgen announced plans by shareholders to reduce their holdings by up to 6% of the company's shares, primarily due to personal funding needs [11] - Shutaishen reported that its major shareholder, Xiangtang Group, reduced its stake by 336,070 shares, decreasing its holding from 7.69% to 6.99% [12]

Policy Developments - The State Council approved the "Implementation Plan for Strengthening Basic Medical and Health Services," emphasizing the importance of enhancing grassroots medical service capabilities and promoting the Healthy China initiative [3] Drug and Medical Device Approvals - Baiotai announced that its Adalimumab injection (Qletli) received marketing approval from the UK's MHRA, expanding the company's overseas product offerings and potentially positively impacting long-term performance [5] - Zhixiang Jintai received clinical trial approval for its GR1803 injection for systemic lupus erythematosus, a dual-specific antibody drug targeting BCMA and CD3, which could treat B-cell mediated autoimmune diseases [6] - Haili Biological's subsidiary received acceptance for a Class III medical device registration application for natural bone repair materials [7] - Xinlitai obtained a drug registration certificate for Enarodustat tablets, aimed at treating anemia in chronic kidney disease patients undergoing dialysis [9] Market Movements - Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. was approved for listing on the New Third Board, with projected revenues of 446 million yuan and 418 million yuan for 2023 and 2024 respectively [11] - Palin Bio announced a share transfer agreement with China Biologic, transferring approximately 200 million shares for about 4.699 billion yuan, representing 21.03% of the company's total shares [12] Industry Trends - Novo Nordisk announced a global workforce reduction of approximately 9,000 positions, about 11% of its total employees, as part of a restructuring plan aimed at achieving annual cost savings of around 8 billion Danish kroner by 2026 [15]

证券日报网讯9月10日晚间，海利生物（603718）发布公告称，控股子公司瑞盛生物的三类医疗器械"天 然骨修复材料"注册申请获得国家药监局受理。该产品适用于颌骨缺损修复，采用更高效生产工艺，骨 修复效果更快更稳定。产品获批上市后，将在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

格隆汇9月10日丨海利生物(603718.SH)公布，控股子公司陕西瑞盛生物科技有限公司（简称"瑞盛生 物"）于近日收到国家药品监督管理局下发的医疗器械注册申请受理通知信息，产品名称：天然骨修复 材料。本产品骨修复材料，根据《医疗器械分类规则》（局令第15号）、《医疗器械分类目录》（2017 年第104号公告），本产品为Ⅲ类医疗器械，属于17口腔科器械，一级产品类别为"17-08口腔植入及组 织重建材料"，二级产品类别为"17-08-06骨填充及修复材料"，产品分类编码为17-08-06。该产品获批上 市后可在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

海利生物公告，控股子公司陕西瑞盛生物科技有限公司于近日收到国家药品监督管理局下发的医疗器械 注册申请受理通知。该医疗器械为天然骨修复材料，适用于颌骨缺损修复。受理号为CQZ2501670，产 品类别为第三类医疗器械。目前注册申请已获得受理，后续需经过审评审批、制证等流程。该产品为Ⅲ 类医疗器械，获批上市后将在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...